Patents by Inventor Tongwen Wang

Tongwen Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody to SNIP1
    Patent number: 6906179
    Abstract: The invention provides novel compositions comprising a Smad protein and an isolated protein component of the proteasome-mediated degradation pathway. The invention also provides novel compositions comprising a Smad1 protein and a substrate for proteasome-mediated degradation. The invention also provides methods of screening for compounds that modulate the interaction between the proteins comprising these compositions. The invention also provides methods of screening for compounds that modulate the activity of the proteins comprising these compositions. The invention also provides methods of detecting proteasome-mediated degradation of novel Smad interacting proteins. A further aspect of the invention is a kit for detecting proteasome-mediated degradation of novel Smad interacting proteins. The invention also provides methods of treating diseases which are associated with aberrant levels of activity of a TGF-? superfamily member.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: June 14, 2005
    Assignee: The General Hospital Corporation
    Inventor: Tongwen Wang
  • Compositions and methods for modulating TGF-beta signaling
    Publication number: 20020076799
    Abstract: The invention provides novel compositions comprising a Smad protein and an isolated protein component of the proteasome-mediated degradation pathway. The invention also provides novel compositions comprising a Smad1 protein and a substrate for proteasome-mediated degradation. The invention also provides methods of screening for compounds that modulate the interaction between the proteins comprising these compositions. The invention also provides methods of screening for compounds that modulate the activity of the proteins comprising these compositions. The invention also provides methods of detecting proteasome-mediated degradation of novel Smad interacting proteins. A further aspect of the invention is a kit for detecting proteasome-mediated degradation of novel Smad interacting proteins. The invention also provides methods of treating diseases which are associated with aberrant levels of activity of a TGF-&bgr; superfamily member.
    Type: Application
    Filed: August 10, 2001
    Publication date: June 20, 2002
    Inventor: Tongwen Wang
  • Methods and compositions for enhancing cellular response to TGF-.beta. ligands
    Patent number: 5912224
    Abstract: The present invention concerns the TGF-.beta. receptor-mediated signaling pathway. The invention is based on the unexpected finding that TGF-.beta. receptor-mediated signaling is inhibited by the cytoplasmic interactor FKBP12. The invention further concerns methods and pharmaceutical compositions for enhancing cellular response to TGF-.beta. ligands. A screening assay is also provided for identifying macrolide potentiators capable of binding FKBP12 and thereby blocking FKBP12-inhibition of TGF-.beta. receptor-mediated signaling.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: June 15, 1999
    Assignee: The General Hospital Corporation
    Inventors: Patricia K. Donahoe, Tongwen Wang